Pablo Llerena

Pablo Llerena

Auto-generated profile, based on publicly available information

Pablo Llerena

Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
EMEric V. Mastrolonardo
Eric V. Mastrolonardo
KNKathryn L. Nunes
Kathryn L. Nunes
PLPablo Llerena
Pablo Llerena
ANAnastasia Nikitina
Anastasia Nikitina
ASAnastasia Sobol
Anastasia Sobol
ALAdam J. Luginbuhl
Adam J. Luginbuhl
Purpose: We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response. Patients and Methods: Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 orally daily (NCT03854032). In the combination arm, BMS986205 was initiated 7 days prior to nivolumab. Patients were stratified by human papillomavirus (HPV) status. Response-adaptive surgical timing involved response assessment by radiographic criteria 4 weeks after treatment with nivolumab in both arms. Nonresponders underwent surgical resection, whereas responders received 4 more weeks of randomized therapy before surgery. Biomarker analysis utilized pathologic treatment response (pTR) and RNA sequencing. Results: Forty-two patients were enrolled, and the addition of IDOi to nivolumab did not result in greater rate of radiographic response (P = 0.909). Treatment was well tolerated, with only 2 (5%) patients experiencing grade 3 immune-related adverse events. The addition of IDOi augmented rates of pTR in patients with high baseline IDO1 RNA expression (P < 0.05). Response-adaptive surgical timing demonstrated reliability in differentiating pathologic responders versus nonresponders (P = 0.009). A pretreatment NK cell signature, PD-L1 status, and IFN-γ expression in the HPV− cohort correlated with response. The HPV+ cohort found B-cell and cancer-associated fibroblast signatures predictive of response/nonresponse. Conclusions: Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status–dependent signatures predicting response to immunotherapy in HNSCC warrant further study.

11 September 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
PLPablo Llerena
Pablo Llerena
HSHani Samarah
Hani Samarah
KNKathryn Nunes
Kathryn Nunes
ZLZhao Lin
Zhao Lin
KBKelly Bridgham
Kelly Bridgham
JCJoseph M. Curry
Joseph M. Curry
Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8+ T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.

12 November 2024 in The Laryngoscope
Verified
Journal Article
Closed access
KNKathryn L. Nunes
Kathryn L. Nunes
VJVictor Jegede
Victor Jegede
DMDerek S. Mann
Derek S. Mann
PLPablo Llerena
Pablo Llerena
RWRichard Wu
Richard Wu
JCJoseph M. Curry
Joseph M. Curry

12 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RZRalph G. Zinner
Ralph G. Zinner
EMEric V. Mastrolonardo
Eric V. Mastrolonardo
JJJennifer M. Johnson
Jennifer M. Johnson
KNKathryn Nunes
Kathryn Nunes
PLPablo Llerena
Pablo Llerena
DCDavid M. Cognetti
David M. Cognetti
Purpose: In locally advanced resectable squamous cell carcinoma of the head and neck (SCCHN), patients treated with neoadjuvant chemotherapy with major pathologic response (MPR) or pathologic complete response (pCR) have overall survival (OS) rates superior to those of patients with poorer pathologic responses. To improve efficacy, we added the PD-1 inhibitor nivolumab to neoadjuvant chemotherapy and evaluated the combination. Patients and Methods: In this single-arm, open-label phase II trial, patients with newly diagnosed stage III to IV human papillomavirus (HPV)–negative SCCHN in the oral cavity, oropharynx, hypopharynx, and larynx or stage II to III HPV-positive oropharyngeal SCCHN received neoadjuvant carboplatin and paclitaxel (6 weeks) plus nivolumab (every other week), followed by surgery and adjuvant radiotherapy ± chemotherapy. The primary endpoint was pCR at the primary site. Results: Thirty-four patients were enrolled and received neoadjuvant therapy. Thirty-three patients received surgery (R0 resection = 100%). Disease sites included the oral cavity (79%), oropharynx (12%), hypopharynx (6%), and larynx (3%). Twenty-eight (85%) patients had stage IVA disease. The median postsurgical follow-up was 35.3 months. Fourteen (41%) patients had grade 3/4 treatment-related adverse events. Twenty-seven (82%) patients completed all cycles of neoadjuvant therapy. Twenty-four (73%) patients had at least an MPR at the primary site, and 15 (45%) had a pCR. In an unplanned analysis at 3 years, recurrence-free survival and OS were 74% and 83%, respectively. Conclusions: This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN. See related commentary by Anderson and Sikora, p. 4763

15 July 2025 in The Laryngoscope
Verified
Journal Article
Open access
PLPablo Llerena
Pablo Llerena
PKPraneet Kaki
Praneet Kaki
JDJefferson DeKloe
Jefferson DeKloe
SKSooji Kim
Sooji Kim
JJJulian Jackson
Julian Jackson
CHColin Huntley
Colin Huntley
Objective: This study aims to investigate the medical management of obstructive sleep apnea ( OSA ) utilizing continuous positive airway pressure ( CPAP ) by the Otolaryngology departments within a tertiary care institution. Methods: Data was retrospectively reviewed from electronic medical records over 12 months. Patients were categorized into two cohorts based on the department managing their treatment with CPAP therapy: Otolaryngology or Sleep Medicine. Loss to follow‐up was defined as the absence of a follow‐up appointment within the first 12 months after prescription. Two‐tailed t ‐tests and multivariable regression analysis were performed. Results: Of 242 total patients included, 65 (26.9%) received CPAP from Otolaryngology and 177 (73.1%) from Sleep Medicine. Otolaryngology patients exhibited significantly higher CPAP compliance, defined as usage ≥ 4 h/night over 30 days, over the first 30 (88% vs. 47%, p < 0.001) and over the last 30 (54% vs. 37%, p = 0.031) days of usage, respectively, compared to General Sleep patients. Loss to follow‐up rates did not differ between the two cohorts. Multivariable analysis found White race to be associated with higher CPAP compliance over the first 30 days ( OR 6.39, 95% CI 1.29–46.5, p = 0.03). Management of CPAP by Otolaryngology was independently associated with increased CPAP compliance over the first ( OR 8.02, 95% CI 3.80–19.1, p < 0.001) and last 30 days ( OR 1.99, 95% CI 1.06–3.75, p = 0.032), respectively. Conclusion: Comprehensive management of OSA , including both medical and surgical interventions, can be successfully performed by the Otolaryngologist–Head and Neck Surgeon. Level of Evidence: 3.